Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Huadan Xue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4278-2165; OpenAlex author ID A5023045297, A5081843212, A5109172354. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers

Papers 18

  1. Integrating Radiomics and Computational Pathology to Predict Early Recurrence of Pancreatic Ductal Adenocarcinoma and Uncover Its Biological Basis in Tumor Mic… Last author DOI 10.1002/advs.202523985↗
  2. Feasibility of Dynamic Volume Perfusion CT for Treatment Response Monitoring in Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.acra.2026.08.112↗
  3. Safety and oncologic efficacy of robotic surgery compared to open surgery after neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.1186/s12893-026-03942-9↗
  4. Comparison of Perfusion CT and Conventional Thin-slice Multiphase CT in the Diagnosis of Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.acra.2025.03.049↗
  5. Erratum: Chinese expert consensus on imaging assessment of pancreatic ductal adenocarcinoma (PDAC) resectability. Co-author DOI 10.1097/jp9.0000000000000235↗
  6. Quantitative MR imaging biomarkers for distinguishing inflammatory pancreatic mass and pancreatic cancer-a systematic review and meta-analysis. Co-author DOI 10.1007/s00330-024-10720-9↗
  7. Computed Tomography-based Radiomics Evaluation of Postoperative Local Recurrence of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.acra.2022.05.019↗
  8. A systematic review of prognosis predictive role of radiomics in pancreatic cancer: heterogeneity markers or statistical tricks? Last author DOI 10.1007/s00330-022-08922-0↗
  9. Optical magnetic multimodality imaging of plectin-1-targeted imaging agent for the precise detection of orthotopic pancreatic ductal adenocarcinoma in mice. Last author DOI 10.1016/j.ebiom.2022.104040↗
  10. Distinguishing pancreatic cancer and autoimmune pancreatitis with in vivo tomoelastography. Co-author DOI 10.1007/s00330-020-07420-5↗
  11. Assessment of Response to Chemotherapy in Pancreatic Cancer with Liver Metastasis: CT Texture as a Predictive Biomarker. Last author DOI 10.3390/diagnostics11122252↗
  12. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Last author DOI 10.1016/j.ejrad.2019.02.009↗
  13. Differentiation of atypical non-functional pancreatic neuroendocrine tumor and pancreatic ductal adenocarcinoma using CT based radiomics. Last author DOI 10.1016/j.ejrad.2019.05.024↗
  14. Image quality of mean temporal arterial and mean temporal portal venous phase images calculated from low dose dynamic volume perfusion CT datasets in patients … Co-author DOI 10.1016/j.ejrad.2016.09.024↗
  15. CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery. Co-author DOI 10.1097/md.0000000000002664↗
  16. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0116803↗
  17. Clinical Value of Dual-energy CT in Detection of Pancreatic Adenocarcinoma: Investigation of the Best Pancreatic Tumor Contrast to Noise Ratio. Co-author DOI 10.1016/s1001-9294(13)60003-6↗
  18. Anti-CXCR4 monoclonal antibody conjugated to ultrasmall superparamagnetic iron oxide nanoparticles in an application of MR molecular imaging of pancreatic canc… Last author DOI 10.1258/ar.2012.120055↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhengyu Jin · 13 shared papers, 2012–2025 · strength 1.92
  2. Liang Zhu · 6 shared papers, 2015–2025 · strength 0.93
  3. Zhiyong Liang · 4 shared papers, 2015–2026 · strength 0.62
  4. Sihang Cheng · 3 shared papers, 2019–2022 · strength 0.52
  5. Menghua Dai · 2 shared papers, 2021–2025 · strength 0.38
  6. Yuejuan Cheng · 2 shared papers, 2019–2025 · strength 0.36
  7. Hebing Chen · 1 shared paper, 2026 · strength 0.36
  8. Ming He · 2 shared papers, 2019–2025 · strength 0.35
  9. Huanwen Wu · 3 shared papers, 2015–2026 · strength 0.35
  10. Zihe Wang · 1 shared paper, 2024 · strength 0.31
  11. Jie Tian · 2 shared papers, 2019–2022 · strength 0.26
  12. Xinming Zhao · 1 shared paper, 2025 · strength 0.26
  13. Pengyu Li · 1 shared paper, 2026 · strength 0.25
  14. Min Dai · 1 shared paper, 2026 · strength 0.25
  15. Wen-Jing Liu · 1 shared paper, 2026 · strength 0.25
  16. Haitao Zhang · 1 shared paper, 2026 · strength 0.25
  17. Xianlin Han · 1 shared paper, 2026 · strength 0.24
  18. Cheng Si-Hang · 1 shared paper, 2026 · strength 0.24
  19. Jing Wu · 1 shared paper, 2026 · strength 0.24
  20. Juan Li · 1 shared paper, 2025 · strength 0.22
  21. Ming He · 1 shared paper, 2023 · strength 0.19
  22. Yuhan Gao · 1 shared paper, 2022 · strength 0.16
  23. Xiaolong Liang · 1 shared paper, 2022 · strength 0.16
  24. Liang Zhu · 1 shared paper, 2022 · strength 0.16
  25. Wenjia Zhang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.